Argenica Therapeutics (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.
The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.
Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.
Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.
Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。